Skip to main content

Trade-Ideas LLC identified

Affymetrix

(

AFFX

) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified Affymetrix as such a stock due to the following factors:

  • AFFX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $11.9 million.
  • AFFX has traded 118.328000000000002955857780762016773223876953125 options contracts today.
  • AFFX is making at least a new 3-day high.
  • AFFX has a PE ratio of 108.
  • AFFX is mentioned 1.61 times per day on StockTwits.
  • AFFX has not yet been mentioned on StockTwits today.
  • AFFX is currently in the upper 20% of its 1-year range.
  • AFFX is in the upper 35% of its 20-day range.
  • AFFX is in the upper 45% of its 5-day range.
  • AFFX is currently trading above yesterday's high.

TheStreet Recommends

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AFFX with the Ticky from Trade-Ideas. See the FREE profile for AFFX NOW at Trade-Ideas

More details on AFFX:

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level. The company operates in two segments, Affymetrix Core and eBioscience. AFFX has a PE ratio of 108. Currently there is 1 analyst that rates Affymetrix a buy, 1 analyst rates it a sell, and 5 rate it a hold.

The average volume for Affymetrix has been 2.4 million shares per day over the past 30 days. Affymetrix has a market cap of $1.1 billion and is part of the technology sector and electronics industry. The stock has a beta of -0.72 and a short float of 13% with 11.09 days to cover. Shares are up 39.1% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Affymetrix as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow.

Highlights from the ratings report include:

  • Despite its growing revenue, the company underperformed as compared with the industry average of 4.0%. Since the same quarter one year prior, revenues slightly increased by 2.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
  • The current debt-to-equity ratio, 0.37, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 2.88, which clearly demonstrates the ability to cover short-term cash needs.
  • The gross profit margin for AFFYMETRIX INC is currently very high, coming in at 70.55%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 4.24% trails the industry average.
  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry average. The net income has decreased by 21.5% when compared to the same quarter one year ago, dropping from $5.17 million to $4.06 million.
  • Net operating cash flow has significantly decreased to $2.28 million or 84.98% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.